Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 August 2022 | Story Anthony Mthembu | Photo Supplied
Katleho Nkosi
Katleho Nkosi’s design, which won him second place in the national design competition during the Student Entrepreneurship Week 2022.

Katleho Nkosi, a fourth-year Education student at the University of the Free State (UFS), obtained second place in a national design competition hosted virtually by Entrepreneurship Development in Higher Education (EDHE). 

The national design competition formed part of the launch of the Student Entrepreneurship Week 2022, which took place at the University of Venda on 18 August 2022. As such, students from many of the universities in the country, including Nkosi, took part in designing a poster that would be used to advertise the event. 

Nkosi is delighted and excited about this accomplishment. “This win was really surprising and unbelievable for me, because obtaining the second-place position means that my work is good,” said Nkosi.

The participants were allowed to conceptualise and submit their final product between 28 June and 15 July 2022. “I had no experience in this space, I only designed content for fun, and I participated in this competition because I was motivated by a friend,” Nkosi highlighted. 

Click to view document  Click here to view poster in full size.


The motivation behind the design

Since the Student Entrepreneurship Week was held at the University of Venda, Nkosi used the vibrancy and colourfulness of Venda as inspiration for his design. “When I was designing the poster, the only thing on my mind was making sure that I put something together that was related to Venda,” he explained. In addition, the theme for the Entrepreneurship Week was ‘Move to Market’, and Nkosi asserts that he tried to integrate the theme with Venda, and this is how the design came about.

The outcome of the competition and future plans

Although Nkosi did not win the competition, he did receive a cash prize for being among the top three. Furthermore, given his accomplishment, Nkosi would like to take part in many more design competitions moving forward. “Now that I have realised that I have the potential to win, I think I can take this as a career path in the future,” he said. Nkosi is also looking at merging his love of teaching with his newfound love for design. “I’m going to try and find the connection between design and education, because I really love to teach, so I could perhaps become a design teacher,” Nkosi expressed

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept